Data Insights

DB-1311 by BioNTech for Solid Tumor: Likelihood of Approval

DB-1311 is under clinical development by BioNTech and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - DB-1311 in Solid Tumor

Data Insights

DB-1303 by BioNTech for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

DB-1303 is under clinical development by BioNTech and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive...

Likelihood of Approval and Phase Transition Success Rate Model - DB-1303 in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

Data Insights

DB-1303 by BioNTech for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

DB-1303 is under clinical development by BioNTech and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to...

Likelihood of Approval and Phase Transition Success Rate Model - DB-1303 in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

BNT-161 by BioNTech for Seasonal Influenza: Likelihood of Approval

BNT-161 is under clinical development by BioNTech and currently in Phase III for Seasonal Influenza. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-161 in Seasonal Influenza

Data Insights

BNT-161 by BioNTech for Influenzavirus B Infections: Likelihood of Approval

BNT-161 is under clinical development by BioNTech and currently in Phase III for Influenzavirus B Infections. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-161 in Influenzavirus B Infections

Data Insights

BNT-161 by BioNTech for Influenzavirus A Infections: Likelihood of Approval

BNT-161 is under clinical development by BioNTech and currently in Phase III for Influenzavirus A Infections. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-161 in Influenzavirus A Infections

Data Insights

BNT-211 by BioNTech for Testicular Cancer: Likelihood of Approval

BNT-211 is under clinical development by BioNTech and currently in Phase II for Testicular Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Testicular Cancer

Data Insights

BNT-321 by BioNTech for Solid Tumor: Likelihood of Approval

BNT-321 is under clinical development by BioNTech and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-321 in Solid Tumor

Data Insights

BNT-111 by BioNTech for Metastatic Melanoma: Likelihood of Approval

BNT-111 is under clinical development by BioNTech and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-111 in Metastatic Melanoma

Data Insights

BNT-111 by BioNTech for Melanoma: Likelihood of Approval

BNT-111 is under clinical development by BioNTech and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-111 in Melanoma

Data Insights

BNT-164 by BioNTech for Tuberculosis: Likelihood of Approval

BNT-164 is under clinical development by BioNTech and currently in Phase II for Tuberculosis. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-164 in Tuberculosis

Data Insights

BNT-211 by BioNTech for Peritoneal Tumor: Likelihood of Approval

BNT-211 is under clinical development by BioNTech and currently in Phase II for Peritoneal Tumor. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Peritoneal Tumor

Data Insights

BNT-211 by BioNTech for Fallopian Tube Cancer: Likelihood of Approval

BNT-211 is under clinical development by BioNTech and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Fallopian Tube Cancer

Data Insights

BNT-211 by BioNTech for Uterine Cancer: Likelihood of Approval

BNT-211 is under clinical development by BioNTech and currently in Phase II for Uterine Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Uterine Cancer

Data Insights

BNT-211 by BioNTech for Non-Small Cell Lung Cancer: Likelihood of Approval

BNT-211 is under clinical development by BioNTech and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Non-Small Cell Lung Cancer

Data Insights

BNT-211 by BioNTech for Endometrial Cancer: Likelihood of Approval

BNT-211 is under clinical development by BioNTech and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Endometrial Cancer

Data Insights

BNT-211 by BioNTech for Sarcomas: Likelihood of Approval

BNT-211 is under clinical development by BioNTech and currently in Phase II for Sarcomas. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Sarcomas

Data Insights

BNT-211 by BioNTech for Gastric Cancer: Likelihood of Approval

BNT-211 is under clinical development by BioNTech and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Gastric Cancer

Data Insights

BNT-211 by BioNTech for Ovarian Cancer: Likelihood of Approval

BNT-211 is under clinical development by BioNTech and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - BNT-211 in Ovarian Cancer

Data Insights

PF-07921188 by BioNTech for Herpes Zoster (Shingles): Likelihood of Approval

PF-07921188 is under clinical development by BioNTech and currently in Phase II for Herpes Zoster (Shingles). According to GlobalData, Phase...